UBS maintains Sanofi at Neutral
An UBS analyst maintained Sanofi (EPA: SASY) at Neutral and a price target of $100.00 from a prior price target of %currency%%price%. Prior to this rating, Sanofi had 16 buy ratings, 7...
Strong Buy
or
Sanofi News & Analysis
-
-
Deutsche Bank maintains Sanofi at Hold
A Deutsche Bank analyst maintained Sanofi (EPA: SASY) at Hold and a price target of $85.00. Prior to this rating, Sanofi had 16 buy ratings, 7 hold ratings, and 0 sell ratings. For...
-
Berenberg maintains Sanofi at Hold
A Berenberg analyst maintained Sanofi (EPA: SASY) at Hold and a price target of $105.00 from a prior price target of %currency%%price%. Prior to this rating, Sanofi had 15 buy ratings, 8...
-
Barclays upgrades Sanofi to Overweight
A Barclays analyst upgraded Sanofi (EPA: SASY) from Equalweight to Overweight with a price target of $115.00 from a prior price target of %currency%%price%. Prior to this rating, Sanofi had...
-
Jefferies maintains Sanofi at Buy
A Jefferies analyst maintained Sanofi (EPA: SASY) at Buy and a price target of $120.00. Prior to this rating, Sanofi had 15 buy ratings, 8 hold ratings, and 0 sell ratings. For consensus...
-
UBS maintains Sanofi at Neutral
An UBS analyst maintained Sanofi (EPA: SASY) Neutral at Neutral and a price target of $93.00. Prior to this rating, Sanofi had 15 buy ratings, 8 hold ratings, and 0 sell ratings. For...
-
Sanofi drug to treat 'smoker's lung' clears trial, says report
Sanofi added its "bold" decision to go without earlier-stage clinical COPD trials had shaved years off the development time
-
Sanofi rises as analysts eye results from smoker's lung drug trial
By Scott Kanowsky Investing.com -- Shares in Sanofi SA (EPA:SASY) climbed by more than 5%, as analysts noted the "blockbuster potential" of the French drugmaker's asthma and eczema medicine...
-
Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today
Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial. Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Phase 3...
-
Chronic Myeloid Leukemia Market to Exhibit Significant Growth as Leading Companies Such as Novartis, Ascentage Pharma, Terns Pharmaceuticals, Sanofi, and Others are Exploring the Domain | DelveInsight
New York, USA, March 23, 2023 (GLOBE NEWSWIRE) -- Chronic Myeloid Leukemia Market to Exhibit Significant Growth as Leading Companies Such as Novartis, Ascentage Pharma, Terns...
-
Acer Therapeutics' Product Acquired From Sanofi Fails In Menopause Study
Acer Therapeutics Inc (NASDAQ: ACER) announced topline results from its Phase 2a proof of concept clinical trial to evaluate ACER-801 (osanetant) as a potential treatment for moderate to...
-
European stocks higher; sentiment surges on banking support
By Peter Nurse Investing.com - European stock markets traded sharply higher Friday, with sentiment boosted by moves in both Europe and the United States to support under-pressure lenders,...
-
European stock futures higher; banking support boosts sentiment
By Peter Nurse Investing.com - European stock markets are expected to open higher Friday, with sentiment boosted by moves in both Europe and the United States to support under-pressure...
-
Diabetes Drug Giant Sanofi Cuts Insulin Prices by Up to 78%
French drugmaker Sanofi said it would cut the price of some of its insulin products by as much as 78% in the U.S., joining other big diabetes drugmakers facing pressure over high...
-
: Sanofi to cap price of Lantus insulin at $35
Sanofi SNYFR:SAN said Thursday that it will cut the U.S. list price of Lantus by 78%, and it will also cap out-of-pocket costs at $35 for the same insulin for people with commercial health...
-
Midday movers: First Republic, Illumina, Seagen and more
By Liz Moyer Investing.com -- Stocks are falling as the shutdown of SVB Financial Group (NASDAQ:SIVB) sends shockwaves through the banking sector. Here are the midday movers for March 10. ...
-
Sanofi agrees to $2.9B purchase of Provention Bio in bid to boost diabetes drug
By Scott Kanowsky Investing.com -- Sanofi SA (EPA:SASY) agreed to purchase US-based pharmaceutical firm Provention Bio (NASDAQ:PRVB) in a deal worth approximately $2.9 billion, as the...
-
Provention Bio's $2.9B Acquisition - A Strategic Fit For Sanofi
Sanofi SA (NASDAQ: SNY) has agreed to acquire Provention Bio Inc (NASDAQ: PRVB) for $25.00 per share in cash, representing an equity value of approximately $2.9 billion. The transaction adds...
-
Influenza and COVID -19 Vaccine Market Report (2022 to 2030) - Pfizer Inc., AstraZeneca plc, Sanofi S.A., GlaxoSmithKline plc and Abbott Laboratories
Newark, New Castle, USA, March 13, 2023 (GLOBE NEWSWIRE) -- The global Influenza and COVID -19 vaccine market will be valued at 278.5 billion in 2030; the spike in cases of COVID pandemic...
-
Sanofi hones in on type 1 diabetes in $2.9 billion Provention Bio deal
By Ludwig Burger and Dina Kartit (Reuters) -France’s Sanofi has agreed to acquire Provention Bio for $2.9 billion to bolster its work on type 1 diabetes therapy and to strengthen its drug...
-
Sanofi to buy Provention Bio for $25 per share in deal worth $2.9 billion
Sanofi to buy Provention Bio for $25 per share in deal worth $2.9 billion
-
: Sanofi to buy Provention Bio in deal worth $2.9 billion
French pharmaceutical group Sanofi said Monday that it will buy Provention Bio, Inc., a U.S.-based biopharmaceutical company focused on autoimmune diseases, for $25 per share in cash, in a...
-
Complement-Targeted Therapeutics Market Report (2022 to 2030) – Sanofi, Novartis AG, Pfizer Inc., Dianthus Therapies and Creative Biolabs
Newark, New Castle, USA, March 03, 2023 (GLOBE NEWSWIRE) -- The global complement-targeted therapeutics market is expected to grow at a CAGR of 8.9% from 2022 to 2030, owing to the rising...
-
: Eli Lilly CEO says $35 for monthly insulin ‘should be the new standard in America’
Eli Lilly & Co. said Wednesday it's capping out-of-pocket insulin costs at $35
-
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
The FDA approved Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) and Sanofi SA's (NASDAQ: SNY) Kevzara (sarilumab) for polymyalgia rheumatica (PMR), an inflammatory rheumatic disease, The...
-
Peptide Therapeutics Market Report (2022 to 2030) - Pfizer Inc., Eli Lilly and Company, Sanofi S.A, GlaxoSmithKline plc and Bristol-Myers Squibb Company
Newark, New Castle, USA, March 01, 2023 (GLOBE NEWSWIRE) -- According to a new market research report titled, "Global Peptide Therapeutics Market by Application (Metabolic, Cardiovascular...
-
Hold Sanofi India; target of Rs 6270: ICICI Direct
ICICI Direct recommended hold rating on Sanofi India with a target price of Rs 6270 in its research report dated February 27, 2023.
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
